Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
待确认10由 pixel_crush 发布于 2026/11/18 18:01:35
DOI:10.1016/S2468-1253(21)00338-1
作者:David T Rubin,?Iris Dotan,?Aaron DuVall,?Yoram Bouhnik,?Graham Radford-Smith,?Peter D R Higgins,?Daniel S Mishkin,?Pablo Arrisi,?Astrid Scalori,?Young S Oh,?Swati Tole,?Akiko Chai,?Kirsten Chamberlain
文献类型:期刊论文
补充材料:只需要正文